A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Recruiting

Phase 1

Phase 2

[225Ac]-FPI-1434A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Sponsor:

Fusion Pharmaceuticals Inc.

Code:

NCT03746431

Conditions

Advanced Solid Tumours

Endometrial Cancer

Cervical Cancer

Ovarian Cancer

Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

[111In]-FPI-1547 Injection

[225Ac]-FPI-1434 Injection multi-dose

FPI-1175 Infusion

[225Ac]-FPI-1434 Injection single-dose

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Fusion Pharmaceuticals Inc. on 2025-04-16.